PIONEER 6 compared oral semaglutide to placebo in 3183 patients with T2DM and established CV disease or CV risk factors only [21]
Providers should document baseline weight, vitals, and labs, then repeat labs at 3-6 months to evaluate metabolic response and screen for adverse effects
Adverse Reactions Adverse Reactions Gastrointestinal adverse events were the most commonly reported and were typically mild to moderate in severity
In a statement, the government said the popular drug GLP-1 (glucagon-like peptide-1) had been approved on the condition it would be prescribed only by medical experts to ensure patent safety
If youve been following GLP-1 news, youve probably seen retatrutide mentioned
its also used to lower the risk of cardiovascular death and hospitalization in adults with **heart failure**, and to slow progression in select adults with **chronic kidney disease**see consumer overviews from MedlinePlus and the Mayo Clinic drug monograph for context